Rafferty Asset Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.97M | Buy |
93,128
+19,047
| +26% | +$1.02M | 0.02% | 403 |
|
|
2025
Q1 | $3M | Buy |
74,081
+1,477
| +2% | +$59.8K | 0.01% | 477 |
|
|
2024
Q4 | $2.02M | Sell |
72,604
-17,797
| -20% | -$495K | 0.01% | 645 |
|
|
2024
Q3 | $2.59M | Sell |
90,401
-30,613
| -25% | -$878K | 0.01% | 573 |
|
|
2024
Q2 | $2.84M | Sell |
121,014
-173,099
| -59% | -$4.06M | 0.01% | 548 |
|
|
2024
Q1 | $7.43M | Sell |
294,113
-157,719
| -35% | -$3.98M | 0.03% | 366 |
|
|
2023
Q4 | $10.6M | Buy |
451,832
+268,335
| +146% | +$6.27M | 0.04% | 262 |
|
|
2023
Q3 | $9.28M | Buy |
183,497
+25,225
| +16% | +$1.28M | 0.05% | 244 |
|
|
2023
Q2 | $7.39M | Sell |
158,272
-6,231
| -4% | -$291K | 0.04% | 318 |
|
|
2023
Q1 | $6.29M | Sell |
164,503
-23,296
| -12% | -$891K | 0.04% | 328 |
|
|
2022
Q4 | $10.3M | Buy |
+187,799
| New | +$10.3M | 0.09% | 176 |
|
|
2022
Q2 | – | Sell |
-67,455
| Closed | -$957K | – | 1128 |
|
|
2022
Q1 | $957K | Buy |
67,455
+11,296
| +20% | +$160K | 0.01% | 789 |
|
|
2021
Q4 | $1.19M | Buy |
56,159
+14,135
| +34% | +$299K | 0.01% | 801 |
|
|
2021
Q3 | $939K | Sell |
42,024
-5,024
| -11% | -$112K | 0.01% | 855 |
|
|
2021
Q2 | $1.17M | Sell |
47,048
-222
| -0.5% | -$5.51K | 0.01% | 831 |
|
|
2021
Q1 | $1.37M | Buy |
47,270
+38,448
| +436% | +$1.12M | 0.01% | 701 |
|
|
2020
Q4 | $228K | Buy |
+8,822
| New | +$228K | ﹤0.01% | 951 |
|